

RESULTS PRESENTATION

1Q21

YDUQS



May 12th, 2021

YDUQ
B3 LISTED NM



Índice
Brasil 50 **IBRX 50**

Índice de
Ações com Governança
Corporativa Diferenciada **IGC**

Índice de
Ações com Tag Along
Diferenciado **ITAG**

DISCLAIMER

Rio de Janeiro, May 12th, 2021 - **YDUQS Participações S.A.**, one of the largest private organizations in Brazil's higher education private sector, presents its **results for the first quarter of 2021 (1Q21)**.

The Company's financial information is presented based on consolidated numbers, in Brazilian Reais, in accordance with the Brazilian Corporation Law and the accounting practices adopted in Brazil (BRGAAP), already in accordance with the International Financial Reporting Standards (IFRS), including IFRS-16.

Consolidated results account for Adtalem Brasil Holding Ltda. group as of May 2020 and Grupo Athenas Educacional as of August 2020, except when stated otherwise.

This document may have forward looking statements that are subject to risks and uncertainties that may lead such expectations to not materialize or substantially differ from expectations. These forecasts express the opinion only for the date they were made, and the Company does not undertake to update them in the light of new information.




Thousand students	2020.1 ⁽¹⁾	2021.1	Δ%	2021.1 (ex-acquisitions)	Δ%
Premium	0.9	2.6	189%	1.3	44%
Digital Learning	146	191	31%	186	27%
On-campus	101	71	-30%	61	-40%
Total	248	265	7%	248	0.2%

2021.1 Intake up by 7% YoY

Even in face of an adverse scenario (pandemic, delay in ENEM examination, etc.), intake increased as a result of medicine and digital learning organic growth, in addition to acquisitions.

Intake
(Thousand students)



(1) 2020.1 figures do not include intake from the acquired companies as from May/2020.

(2) Intake considers the period of October-April.



Premium

- We reached the milestone of **6 thousand undergraduate medical students**. New expectation for 2021YE: 6.2-6.6 thousand students
- Medicine **average ticket increase** (+5% y/y)
- Premium **EBITDA margin**: 53%
- **Renewal Rate** + 2,8 p.p. above 1Q20
- **IDOMED**: Medicine new identity



Digital Learning

- **Net Revenue** doubled in a 2y period and increased +38% vs 1Q20
- **Undergraduate Student base** doubled in a 2y period and increased 30% vs 1Q20
- **Renewal Rate** + 0,3 p.p. above 1Q20
- **Centers continue to expand** (+58% vs 1Q20), with 76% of the total number of centers still maturing. 2 thousand centers expected for 2021YE.



On-Campus

- **Average ticket** increased by +4% vs 1Q20
- **Renewal rate** stable in a pandemic context, rising 0.2 p.p.
- **Aura**: 43% of students with access to Ensineme content
- **Mix change**: increase in the representativeness of health courses for the third consecutive year, rising from 30% to 42%

YDUQS



Mandatory discounts referring to laws and court decisions only on a **residual** basis



Bad Debt + Discounts (as % of Net Revenue) at a **stable** level



NPS improvement ⁽¹⁾ Apr/21 YTD

On-campus: +17 p.p.
Digital Learning: +21 p.p.



Solid Capital Structure, with low leverage



Acquisitions: More than 95 million⁽²⁾ reais captured in synergies



Increase in Premium and DL representativeness, totaling 46% of net revenue



(1) NPS results referring to Estácio graduation, values updated until April 30, 2021.
(2) amounts annualized and in regime.

Our backbone in Digital Learning drives our business units

New content models continue to increase student satisfaction ...

- **+17 p.p. increase** in the NPS level for students in Digital Learning and **+21 p.p. increase** for students in on-campus

...and with that we are increasing our reach in graduation...

- Digital operation allows EnsineMe to **scale** its solutions:
 - 1.1k courses produced in 12 months
 - **40% of content optimized in new demands**
 - all White-label contente
- With this scale, we have already attended the digital classes of **100% of the Aura on-site and 73% of the freshmen and 43% of the entire base in Digital Education.**

... and enabling more and faster business expansions

- **+15 100% digital courses** ready for the 2nd semester with minimal investment
- We already enable launches **beyond graduation** without investment in production!
 - 48 extra courses
 - Graduate courses in 6 different local brands




PREMIUM: MEDICINE WITH STRONG ORGANIC GROWTH

YDUQS

1Q21


IBMEC as a strategic asset

Adjusted Net Revenue Premium ⁽¹⁾
(R\$ million)




IBMEC Medicine acquisitions Medicine

Premium Student Base
(Thousand students)



Adjusted EBITDA ⁽¹⁾
(R\$ million)



EBITDA margin ⁽¹⁾ (%)

IDOMED
Instituto de Educação Médica

Launch of the new unified vertical
medicine identity

Undergraduation
6.0K students

Graduation
0.5K students

6.2-6.6K students
Undergraduation base
expected in 2021

Adjusted Average Ticket ⁽¹⁾
R\$8,8k/month | +5% y/y (paying students)

+100 seats
for 2021.2

ibmec

New logo
launch

Undergraduation
5.2K students

Graduation
1K students

Adjusted Average Ticket ⁽¹⁾
R\$2.7K/month (undergraduation)



Premium EBITDA represents 34% of
YDUQS Adjusted EBITDA ⁽¹⁾



Laws and court decisions impact of
R\$8.3 million (vs R\$18 million on
4Q20), in Medicine NR in 1Q21



Renewal Rate ⁽²⁾ at 96.5%, registering
an increase of 2.8 p.p. vs the same
period of the previous year



⁽¹⁾ Net revenue adjusted for the effects of laws and court decisions to Covid-19 | Adjusted EBITDA for non-recurring effects.

⁽²⁾ Data until 04/30/21. When calculating the renewal rate, only the Estácio + Unitoledo student base is considered for a better comparison with the previous year.


DIGITAL LEARNING: NET REVENUE DOUBLING IN 2 YEARS

YDUQS

1Q21


Net Revenue
(R\$ million)

Undergraduation Lifelong



Adjusted EBITDA⁽¹⁾
(R\$ million)


Expected EBITDA
1H21



EBITDA of Digital Learning represents 35% of YDUQS total Adjusted EBITDA⁽¹⁾

Student Base
(thousand students)

Undergraduation Lifelong




In 1Q21, the Digital Learning **average ticket** registered R\$240/month, a slight 1.8% y/y decrease



Renewal Rate⁽²⁾ of 77.4% registering an increase of 0,3 p.p. vs same period in the previous year

Number of centers
(#)



(1) EBITDA adjusted by non-recurring effects.


(2) Data until 04/30/21. When calculating the renewal rate, only the Estácio + Unitoledo student base is considered for a better comparison with the previous year.



ON-CAMPUS: RESULTS BOOSTED BY ACQUISITIONS


Growing average ticket

Net Revenue
(R\$ million)




ex-acquisitions

ex-FIES



Adjusted EBITDA⁽¹⁾
(R\$ million)

Expected EBITDA
1H21




17% EBITDA margin ⁽¹⁾(%)




On-campus EBITDA represents 30% of YDUQS total Adjusted EBITDA ⁽¹⁾

Undergraduation Average Ticket
(R\$/month) (ex-semi on-campus)




ex-acquisitions

ex-FIES



Student Base⁽¹⁾
(Thousand students)



Renewal Rate⁽²⁾ at 84.9% registering a 0,2 p.p. increase over the same period of the previous year

(1) In 1Q21, the student base considers the late intake of students..


(2) Data until 04/30/21. When calculating the renewal rate, only the Estácio + Unitoledo student base is considered for a better comparison with the previous year.



ON-CAMPUS: BU IN STRUCTURAL EVOLUTION


With improvement in operational research and student satisfaction

Mix of courses on-campus
(%, Estácio ex-Medicine)




Mix of the on-campus student base changing, with greater representativeness of health courses, which reach almost half of the total on-campus base

Renewal Rate ex-acquisitions
(%, Undergraduation ex-premium)




Maintenance of a constant renewal rate, as a result of greater renewal efforts, even in an adverse scenario

Students per class ratio and occupancy rate
(# students, %)




On-campus segment continues to advance in operational research, with improvement in students per class ratio and class occupancy rate

Evolution of the NPS variation
(p.p, Estácio)





NPS continue to grow over the years, expecting to close 2021 up +17 p.p.

Percentage of students at Aura
(%)



YDUQS

● On-campus ● Digital Learning ● Premium




10




ADJUSTED COSTS AND EXPENSES


Breakdown of adjusted costs and expenses⁽²⁾
(R\$ million; 1Q21 vs 1Q20)



Bad Debt + Discounts
(R\$ million)



Costs and expenses + discounts ex-acquisitions and D&A⁽²⁾
(R\$ million)



➤ Considerable reduction in **non-recurring adjustments in costs and expenses** compared to the last quarter.

➤ Greater efforts in 1H21 intake, due to the adverse scenario, boosted **advertising expenses**.

➤ **D&A** varied by R\$ 29 million, impacted by the IFRS 16 effect and the incorporation of acquisitions (R\$ 17 million referring to goodwill).



(1) Acquisitions include Adtalem as from May/20 and Athenas as from Aug/20.
(2) Adjusted for R\$ 5 million of non-recurring items with restructuring and M&A.


ADJUSTED EBITDA

YDUQS

1Q21

Adjusted EBITDA
(R\$ million)


● On-campus ● Digital Learning ● Premium



(1) Acquisitions include Adtale as from May/20 and Athenas as from Aug/20.

ADJUSTED NET INCOME

Adjusted Net Income
(R\$ million)




Account	Description	4Q20	1Q20	1Q21
EBITDA	Non-recurring items from EBITDA	159.8	13.1	13.0
D&A	Trade Fund ⁽¹⁾	18.0	1.9	16.8
Impact on Income		177.8	15.0	29.8

(1) Regarding the amortization of goodwill on acquisitions

CASH FLOW AND CAPEX


Preserving solid financial position, even in an adverse scenario

Reconciliation of Operating Cash Flow
(R\$ million, before Capex)



92% Cash Conversion
(+8 p.p. vs 1Q20)

Reconciliation of OCF	1Q20	1Q21
Operating Cash Flow	409	189
Income Taxes and Social Contribution paid	5	11
Loans interest paid	17	46
Increase in Judicial deposits	0,4	10
Contract termination fee ⁽³⁾	-	45
Delay in FIES receivables ⁽⁴⁾	-136	-
OCF after reconciliation	296	301



➤ High liquidity, cash generation and ability to raise funding, **R\$2.0 billion in cash position**

➤ **Low Debt:** Net Debt⁽²⁾/Adjusted EBITDA at **1.3x**

(1) Cash conversion calculated considering Adjusted EBITDA.

(2) Net debt excluding leasing (ex-IFRS16).

(3) In 1Q21, R\$ 45 million refers to the timely payment of termination of the rental agreement, an amount provisioned in the past.

(4) In 1Q20, R\$ 136 million refers to the FIES receivables referring to Dec/19.




RECENT ACQUISITIONS

Capturing synergies within expected schedule


Adtalem

Robust process with the development of an operation model generating learning gains and mapping synergies for new acquisitions



Athenas

Longer schedule due to maturation time for medicine



Other important milestones

Unitoledo

- First integration of YDUQS history with maintenance of teaching brand and maintenance of brand differentials and market positioning
- Conception and implementation of DL private label in 90 days

Adtalem

- Organizational structure implemented in Day 1 with communication for +5,000 employees ensuring business continuity
- Systems fully migrated 8 months after closing (+60 systems)
- Teaching matrix implemented in the first post-closing intake cycle of 21.1

Athenas

- Record intake in 2020.2 and 2021.1, 2 times the all time high pre-closing intake
- Anticipation of 50 medicine seats
- Implementation of DL centers in the first month of integration (46 Estácio centers in the region)
- Incorporation of the Athenas brands by the Estácio brand





(1) amounts annualized and in regime.

STATUS OF THE PERSPECTIVES PRESENTED IN 4Q20

YDUQS

1H21
Guidance

1Q21

Status		
Premium	<ul style="list-style-type: none"> • Increase in medicine base in 2021 as contracted and expansions: 7 units still maturing; 5 new units; 2 processes of increase in seats • Strong H1 intake, Medicine – volume and price 	 <p>Net Revenue R\$400-430 million</p> <p>EBITDA R\$180-210 million</p>
Digital	<ul style="list-style-type: none"> • Strong base increase; 76% of DL centers are still not mature • H1 intake with relevant growth on a strong basis • 2K centers in 2021 e 2.5K+ in 2022 	 <p>Net Revenue R\$640-670 million</p> <p>EBITDA R\$250-280 million</p>
On-campus	<ul style="list-style-type: none"> • NOR FIES impact ~30% of what it was in 2020 • Challenging H1 intake (H2 with good perspective) • Stable Price – perspective of margin recomposition starting from 2022 • Synergies of recent acquisitions impacting results (2021/22) 	 <p>Net Revenue R\$1,180-1,210 million</p> <p>EBITDA R\$200-230 million</p>
In general	<ul style="list-style-type: none"> • Marginal effect of laws and court decisions in Q1 • Good M&A perspectives, with robust financial situation • Positive re-enrollment • New stage of Digital Transformation impacting NPS and retention • Digital and Premium reaching ~50% of NOR in 2021 • Lifelong gaining traction in all BUs 	 <p>Net Revenue R\$2,220-2,310 million</p> <p>EBITDA R\$630-720 million</p>

Quarter presents a significant evolution in performance since the beginning of the pandemic, without relevant adjustments, minimal impact of laws and court decisions and stable bad debt

- Adjustments in 2020: R\$455M / Adjustments in 1Q21: R\$13M
- Discounts by laws and court decisions: de R\$84M (4Q20) to R\$8M
- Bad debt + discounts/net revenue of 12% (1Q20) to 11%

Consistent and effective strategy results in Adjusted EBITDA in line with 1Q20 with the acquisitions and the growth of DL and Premium, offsetting the losses from two weak on-campus intake

- On-campus intake: -30%
- DL+ Premium representativeness in NOR shifting from 21% (1Q18) to 46%
- Adjusted EBITDA added by acquisitions: R\$83M

Positive outlook for 2H21 and 2022 due to the continued growth of DL and Premium, with on-site recovery

- NOR Digital Learning 1H21: +39-46%
- NOR Premium 1H21: +47-58%
- NOR Consolidated 1H21: +12-17%
- Average ticket on-campus (ex-FIES) 1Q21: +6%
- Stable on-campus renovation at + 0.2 pp. and NPS increase

Financial situation remains comfortable

- 92% of operational cash generation
- 1.3x net debt/Adjusted EBITDA
- Cash Position 1Q21: R\$2.0 billion



APPENDIX



MEDICINE STUDENT BASE

6.2-6.6K

students in total
medicine base
expected by the end
of 2021

Possibility of up to **+200 seats** in 2021
considering seat increase in Alagoins and Jaraguá do Sul

+150 new seats in 1Q21

Authorized in March 2021 and inaugurated
and intake started in April 2021

+100 new seats in 2021

Pending MEC authorization

Units	State	Expected	Authorized/ Qualified Seats	Student Base	Full Potential ⁽¹⁾	
					Authorized/ Qualified Seats	Student Base
Presidente Vargas	RJ	-	240	1.610	240	1.728
Città	RJ	-	170	1.041	170	1.224
Juazeiro do Norte	CE	-	100	677	100	720
Ribeirão Preto	SP	-	76	534	76	547
Teresina	PI	-	110	691	110	792
Alagoins	BA	-	65	264	165	1.188
Jaraguá do Sul	SC	-	50	207	150	1.080
Juazeiro	BA	-	155	520	155	1.116
Angra dos Reis	RJ	-	89	295	155	1.116
Canindé	CE	-	50	80	150	1.080
Cáceres	MT	-	50	62	50	360
Castanhal	PA	2021.1	50	-	150	1.080
Quixadá	CE	2021.1	50	2	150	1.080
Açailândia	MA	2021.1	50	-	150	1.080
Total Authorized Seats ⁽²⁾			1.305	5.983	1.971	14.191
Iguatu	CE	2021.2	50	-	150	1.080
Ji-Paraná	RO	2021.2	50	-	150	1.080
Total Qualified Seats			1.405	5.983	2.271	16.351
Athenas ⁽³⁾			-	-	200	-

(1) Assuming seat expansion to maximum capacity (+100 seats/year) in all Mais Médicos units. Student base includes ProUni and FIES.

(2) Authorized seats are qualified seats which received MEC final authorization.

(3) Seats not yet qualified from the acquisition of Athenas Group are under court and/or administrative discussions, with the possibility of up to +200 seats.



INCOME STATEMENT BY BUSINESS UNIT

	Consolidated	Premium	Digital	On-campus
Em R\$ Milhões	1Q21	1Q21	1Q21	1Q21
Gross Revenue	2,057.0	244.6	559.4	1.253.0
Monthly tuition fees	2,047.9	243.0	557.5	1,247.4
Other	9.0	1.6	1.8	5.6
Net Operating Revenue	(974.7)	(42.5)	(269.0)	(663.1)
Cost of Services	1,082.3	202.1	290.3	589.9
Personnel	(456.8)	(75.6)	(60.9)	(320.3)
Rent, municipal property tax and other	(276.9)	(56.5)	(18.9)	(201.5)
Third-party services and other	(13.2)	(2.9)	0.4	(10.8)
Depreciation and amortization	(61.1)	(2.9)	(37.0)	(21.2)
Net Operating Revenue	(105.7)	(13.4)	(5.4)	(86.9)
Gross profit	625.5	126.4	229.5	269.6
Gross Margin	57.79%	62.57%	79.04%	45.70%
Selling, G&A and Other Expenses	(466.8)	(47.1)	(135.4)	(284.3)
Personnel	(86.6)	(12.5)	(28.8)	(45.2)
Advertising	(156.2)	(7.0)	(49.2)	(100.0)
Bad Debt	(95.4)	(4.0)	(28.2)	(63.2)
Other Expenses	(85.6)	(16.3)	(16.3)	(53.0)
Other Revenue	5.8	0.2	2.2	3.3
Depreciation and amortization	(48.7)	(7.5)	(15.0)	(26.2)
(+) Depreciation and amortization	154.4	20.8	20.4	113.2
EBITDA	313.1	100.2	114.5	98.4
EBITDA Margin (%)	28.9%	49.6%	39.4%	16.7%
Adjusted EBITDA ⁽¹⁾	326.1	111.8	115.5	98.8
Adjusted EBITDA margin(%)	29.9%	53.1%	39.8%	16.7%
Discounts	(29.0)	(1.3)	(6.2)	(21.5)
Fees and interest on delays	9.5	1.1	3.1	5.2

(1) Adjusted by non-recurring items (restructuring, consulting services and other)





IR Contact

Mayte Albuquerque | Guilherme Lahr | Rosimere Nunes | Milena Gonçalves

+55 (21) 3311-9875 | 3311-9290

ri@yduqs.com.br

www.yduqs.com.br